Relevant bibliographies by topics / Intravitreal bevacizumab

Contents

  1. Journal articles
  2. Dissertations / Theses
  3. Books
  4. Book chapters

Academic literature on the topic 'Intravitreal bevacizumab'

Author: Grafiati
Published: 3 June 2025
Last updated: 31 July 2025

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the lists of relevant articles, books, theses, conference reports, and other scholarly sources on the topic 'Intravitreal bevacizumab.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Journal articles on the topic "Intravitreal bevacizumab"

1

Shahid, Muhammad Hamza, Faisal Rashid, Saba Tauqeer, Rabab Ali, Muhammad Talha Farooq, and Nouman Aleem. "Comparison of Suprachoroidal Triamcinolone Injection with Intravitreal Bevacizumab Vs Intravitreal Bevacizumab only in Treatment of Refractory Diabetic Macular Edema." Pakistan Journal of Medical and Health Sciences 16, no. 6 (2022): 301–3. http://dx.doi.org/10.53350/pjmhs22166301.

Full text
Abstract:
Background: Macular edema due to diabetic retinopathy is among the most common causes of blindness in diabetics from working age group around the world . Diabetic macular edema which involves the center of the macula is among the major cause of visual decline in patients with diabetes mellitus. Intra-Vitreal Triamcinolone Acetonide with intravitreal Bevacizumab and intravitreal Bevacizumab only have been in practice as treatment options for cases not responsive to anti-vascular endothelial growth factor agents. Objective: To compare safety and efficacy profile of suprachoroidal injection of tr
APA, Harvard, Vancouver, ISO, and other styles
2

Hussein, Zaid R. "Indications of Intravitreal Injection of Bevacizumab in a sample of Iraqi patients." AL-Kindy College Medical Journal 14, no. 2 (2019): 79–83. http://dx.doi.org/10.47723/kcmj.v14i2.57.

Full text
Abstract:
Background: Anti-vascular endothelial growth factors commonly used intravitreally for treatment of variable retinal disease worldwide, which help to regulate the upregulation of vascular endothelial growth factors due to ischemia or/and other retinal insult.
 Objective: To review all cases of intravitreal bevacizumab given in the retinal unit of the Eye Specialty Private Hospital in Iraq from December 2015 to June 2016, pointing out the common indications.
 Methods: A retrospective study including all cases of intravitreal injections of bevacizumab recorded at the Eye Specialty Priva
APA, Harvard, Vancouver, ISO, and other styles
3

Sethi, Muhammad Junaid, Umer Khan, Natasha Junaid, Nazli Gul, Ishan Ullah, and Muhammad Israr. "Visual Results of Intravitreal Bevacizumab (Avastin) Treatment for Branch Retinal Vein Occlusion a Multi Center Study." Pakistan Journal of Medical and Health Sciences 17, no. 2 (2023): 811–13. http://dx.doi.org/10.53350/pjmhs2023172811.

Full text
Abstract:
Objective: To evaluate the visual outcomes in patients with branch retinal vein obstruction after intravitreal bevacizumab (Avastin) injection. Study Location and Duration:, Department of Ophthalmology Abaseen hospital and Khyber medical center Peshawar from January 2019 to January 2022 both department conducted this multi-center study. Methodology: Patients with BRVO received at least one intravitreal Bevacizumab (Avastin) injection of 1.25 mg in 0.05 ml. Snellen visual acuity tests, Fundus Fluorescein Angiography (FFA), and Optical Coherence Tomography were used to assess the patients (OCT).
APA, Harvard, Vancouver, ISO, and other styles
4

Peters, Swaantje, Peter Heiduschka, Karl-Ulrich Bartz-Schmidt, and Ulrich Schraermeyer. "Penetration of Bevacizumab into the Iris, Anterior Chamber Angle and Ciliary Body After Intravitreal Injection." European Ophthalmic Review 03, no. 01 (2009): 36. http://dx.doi.org/10.17925/eor.2009.03.01.36.

Full text
Abstract:
Recently, it was suggested that the anti-vascular endothelial growth factor (VEGF) antibody bevacizumab could be used in the treatment of rubeosis iridis. Therefore, we aimed to trace the penetration of bevacizumab into the anterior chamber after intravitreal injection of the drug. We found that intravitreally injected bevacizumab penetrates well and quickly into the anterior chamber angle, iris and ciliary body. The highest concentration of bevacizumab is present on days one to four after injection, with penetration into the iris appearing to be faster than that into the anterior chamber angl
APA, Harvard, Vancouver, ISO, and other styles
5

Lucas, Raj S., Hamish D. R. McKee, and Lawrence R. Lee. "Intravitreal Bevacizumab." Ophthalmology 114, no. 2 (2007): 400. http://dx.doi.org/10.1016/j.ophtha.2006.10.002.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Khamar, BakuleshM. "Intravitreal bevacizumab." Indian Journal of Ophthalmology 66, no. 1 (2018): 173. http://dx.doi.org/10.4103/ijo.ijo_802_17.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

An, Seoung Hyun, and Woo Jin Jeong. "Early-scatter laser photocoagulation promotes the formation of collateral vessels in branch retinal vein occlusion." European Journal of Ophthalmology 30, no. 2 (2019): 370–75. http://dx.doi.org/10.1177/1120672119827857.

Full text
Abstract:
Purpose: To investigate the effect of early-scatter laser photocoagulation on the formation of collateral vessels in branch retinal vein occlusion. Methods: The medical records of 40 cases (40 patients) of branch retinal vein occlusion with macular edema were retrospectively reviewed. Of them, 23 patients were treated with intravitreal bevacizumab injection and 17 patients underwent intravitreal bevacizumab injection with additional laser treatment. Early-scatter laser photocoagulation was applied for capillary non-perfusion areas, regardless of retinal neovascularization. Collateral vessel pr
APA, Harvard, Vancouver, ISO, and other styles
8

Newcott, Eric K., Abdallah A. Ellabban, Shokufeh Tavassoli, and Ahmed Sallam. "Intravitreal Bevacizumab and Triamcinolone for Treatment of Cystoid Macular Oedema Associated with Chronic Myeloid Leukaemia and Imatinib Therapy." Case Reports in Ophthalmological Medicine 2015 (2015): 1–3. http://dx.doi.org/10.1155/2015/713868.

Full text
Abstract:
Purpose.To evaluate the efficacy of intravitreal bevacizumab and triamcinolone in the treatment of cystoid macular oedema in a case with chronic myeloid leukaemia on imatinib treatment.Methods.We treated a 78-year-old man with bilateral cystoid macular oedema with intravitreal triamcinolone and subsequent bevacizumab in one eye and intravitreal bevacizumab, alone, in the fellow eye.Results.Serial intravitreal bevacizumab with and without triamcinolone treated cystoid macular oedema in both eyes and improved the vision.Conclusion.Intravitreal bevacizumab and triamcinolone could be viable option
APA, Harvard, Vancouver, ISO, and other styles
9

Shrestha, Arjun, Rinkal Suwal, Rajan Shrestha, Barsha Suwal, and Deepak Khadka. "Use of Intravitreal Bevacizumab Injection among Patients Undergoing Surgical Retinal Interventions at Tertiary Eye Hospital: A Descriptive Cross-sectional Study." Journal of Nepal Medical Association 59, no. 241 (2021): 858–61. http://dx.doi.org/10.31729/jnma.5515.

Full text
Abstract:
Introduction: Intravitreal Bevacizumab injection has now become a routine procedure for retina specialists throughout the world. Easy availability of this monoclonal antibody molecule even in Nepal has brought a revolution in the management of various retinal diseases. This study aims to find out the prevalence of the use of intravitreal Bevacizumab for retinal diseases at the tertiary eye hospital. Methods: This descriptive cross-sectional study was carried out in the retina department at a tertiary care hospital from January 2017 to December 2019 after obtaining ethical clearance from Nepal
APA, Harvard, Vancouver, ISO, and other styles
10

Ehrlich, Rita, Russell Pokroy, Ori Segal, et al. "Diabetic macular edema treated with ranibizumab following bevacizumab failure in Israel (DERBI study)." European Journal of Ophthalmology 29, no. 2 (2018): 229–33. http://dx.doi.org/10.1177/1120672118782102.

Full text
Abstract:
Purpose: To evaluate the outcome of second-line intravitreal ranibizumab treatment in eyes with diabetic macular edema having persistent edema following initial therapy with intravitreal bevacizumab. Methods: Diabetic macular edema treated with ranibizumab following bevacizumab failure in Israel was a retrospective, multi-center study. Consecutive eyes with persistent diabetic macular edema following at least three previous intravitreal bevacizumab injections prior to intravitreal ranibizumab, at least three-monthly intravitreal ranibizumab injections and at least 12 months of follow-up were i
APA, Harvard, Vancouver, ISO, and other styles
More sources

Dissertations / Theses on the topic "Intravitreal bevacizumab"

1

Moazez, Carmel. "Visual Findings in Neovascular Macular Degeneration Refractory to Bevacizumab after Intravitreal Aflibercept Therapy." Thesis, The University of Arizona, 2016. http://hdl.handle.net/10150/603674.

Full text
Abstract:
A Thesis submitted to The University of Arizona College of Medicine - Phoenix in partial fulfillment of the requirements for the Degree of Doctor of Medicine.<br>Neovascular (wet) age‐related macular degeneration (AMD) is associated with blindness in patient populations above 55 years of age, affecting approximately 2 million Americans. Intravitreal (IV) bevacizumab is widely employed in the treatment of wet AMD. Development of a novel pharmacologic intervention to match bevacizumab’s indications is possible with the advent of aflibercept. This study evaluated the optical coherence tomogra
APA, Harvard, Vancouver, ISO, and other styles
2

Marquez, Tatiana Vieira de Brito. "Estudo comparativo entre o Bevacizumabe intravitreo e a fotocoagulação a laser com oftalmoscopio binocular indireto na retinopatia da prematuridade." Universidade Federal de Goiás, 2010. http://repositorio.bc.ufg.br/tede/handle/tede/4189.

Full text
Abstract:
Submitted by Erika Demachki (erikademachki@gmail.com) on 2015-02-20T15:09:52Z No. of bitstreams: 2 Dissertação - Tatiana Vieira de Brito Marquez - 2010.pdf: 2722177 bytes, checksum: d3f571bcc9c3e44cf51b9d4539e6191d (MD5) license_rdf: 23148 bytes, checksum: 9da0b6dfac957114c6a7714714b86306 (MD5)<br>Approved for entry into archive by Erika Demachki (erikademachki@gmail.com) on 2015-02-20T15:10:12Z (GMT) No. of bitstreams: 2 Dissertação - Tatiana Vieira de Brito Marquez - 2010.pdf: 2722177 bytes, checksum: d3f571bcc9c3e44cf51b9d4539e6191d (MD5) license_rdf: 23148 bytes, checksum: 9da0b6dfac957114
APA, Harvard, Vancouver, ISO, and other styles
3

Christoforidis, John Byron, Karen Briley, Katherine Binzel, et al. "Systemic Biodistribution and Intravitreal Pharmacokinetic Properties of Bevacizumab, Ranibizumab, and Aflibercept in a Nonhuman Primate Model." ASSOC RESEARCH VISION OPHTHALMOLOGY INC, 2017. http://hdl.handle.net/10150/627123.

Full text
Abstract:
PURPOSE. To determine the intravitreal pharmacokinetic properties and to study the systemic biodistribution characteristics of 1-124-labeled bevacizumab, ranibizumab, and aflibercept with positron emission tomography-computed tomography (PET/CT) imaging in a nonhuman primate model. METHODS. Three groups with four owl monkeys per group underwent intravitreal injection with 1.25 mg/0.05 mL 1-124 bevacizumab, 0.5 mg/0.05 mL 1-124 ranibizumab, or 2.0 mg/0.05 mL 1-124 aflibercept in the right eye of each subject. All subjects were imaged using PET/CT on days 0, 1, 2, 4, 8, 14, 21, 28, and 35. Serum
APA, Harvard, Vancouver, ISO, and other styles
4

Sendtner, David [Verfasser], and Isabel [Akademischer Betreuer] Oberacher-Velten. "Trabekulektomie mit Mitomycin C in Kombination mit Bevacizumab - intravitreal, subkonjunktival, intracameral - retrospektive Evaluation des Einflusses von Bevacizumab auf die postoperative Wundheilungsmodulation, den Augendruck, operative Folgeeingriffe und die postoperative antiglaukomatöse Medikation / David Sendtner ; Betreuer: Isabel Oberacher-Velten." Regensburg : Universitätsbibliothek Regensburg, 2020. http://d-nb.info/1204635919/34.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Gomes, Renato Vieira. "Análise comparativa da acuidade visual em pacientes com oclusão de ramo de veia central da retina antes e após tratamento combinado de bevacizumabe intravítreo com fotocoagulação a laser." Niterói, 2012. https://app.uff.br/riuff/handle/1/4741.

Full text
Abstract:
Submitted by Ana Lúcia Torres (bfmhuap@gmail.com) on 2017-09-29T23:29:42Z No. of bitstreams: 2 license_rdf: 0 bytes, checksum: d41d8cd98f00b204e9800998ecf8427e (MD5) DISSERTAÇAO RENATO GOMES.pdf: 1085453 bytes, checksum: 52c34bec90105d63a6d951a99405c02d (MD5)<br>Approved for entry into archive by Ana Lúcia Torres (bfmhuap@gmail.com) on 2017-09-29T23:31:18Z (GMT) No. of bitstreams: 2 license_rdf: 0 bytes, checksum: d41d8cd98f00b204e9800998ecf8427e (MD5) DISSERTAÇAO RENATO GOMES.pdf: 1085453 bytes, checksum: 52c34bec90105d63a6d951a99405c02d (MD5)<br>Made available in DSpace on 2017-09-29T23
APA, Harvard, Vancouver, ISO, and other styles
6

Gib, Roland. "Erfahrungen mit intravitrealem Bevacizumab (Avastin®) bei exsudativer, altersabhängiger Makuladegeneration." Doctoral thesis, Universitätsbibliothek Leipzig, 2013. http://nbn-resolving.de/urn:nbn:de:bsz:15-qucosa-126191.

Full text
Abstract:
Zusammenfassung Dissertation zur Erlangung des akademischen Grades Dr. med. Erfahrungen mit intravitrealem Bevacizumab (Avastin®) bei exsudativer, altersabhängiger Makuladegeneration eingereicht von Roland Gib, geboren am 17.01.1981 in Homburg/Saar angefertigt an der: Klinik und Poliklinik für Augenheilkunde der Universität Leipzig betreut von: Prof. Dr. med. Peter Wiedemann eingereicht im April 2013 Einleitung Die altersabhängige Makuladegeneration (AMD) stellt mit der choroidalen Neovaskularisation (CNV) die häufigste Ursache für eine Erblindung in den westlichen Industrienationen dar. Bei d
APA, Harvard, Vancouver, ISO, and other styles
7

Schneider, Michael. "Retrospektive Studie zur Wirksamkeit der intravitrealen Bevacizumabbehandlung bei diabetischer Retinopathie und retinalem Venenverschluss." Doctoral thesis, Universitätsbibliothek Leipzig, 2011. http://nbn-resolving.de/urn:nbn:de:bsz:15-qucosa-67709.

Full text
Abstract:
Angiogeneseinhibitoren haben innerhalb weniger Jahre die Medizin revolutioniert. Auf dem Gebiet der Augenheilkunde ist es v.a. das Bevacizumab (Avastin ®), welches bei verschiedenen Krankheitsbildern eingesetzt wird, um den Verlust an Sehschärfe zu bekämpfen, der u.a. durch eine Vergrößerung der Netzhautdicke zustande kommt. Diese Arbeit untersucht die Veränderungen von Visus und Netzhautdicke (Makulaödem) an Patienten mit diabetischer Retinopathie (DR) und retinalem Venenverschluss (RVO). Verschiedene Studien zeigen, dass nicht alle Patienten von dieser neuen Therapieform profitieren. Mit dem
APA, Harvard, Vancouver, ISO, and other styles
8

Gib, Roland [Verfasser], Jens [Gutachter] Dawczynski, and Salvatore [Gutachter] Grisanti. "Erfahrungen mit intravitrealem Bevacizumab (Avastin®) bei exsudativer, altersabhängiger Makuladegeneration / Roland Gib ; Gutachter: Jens Dawczynski, Salvatore Grisanti." Leipzig : Universitätsbibliothek Leipzig, 2013. http://d-nb.info/1238527361/34.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Lehmann, Fabian [Verfasser]. "Die Visusstabilität und intravitreale Injektionsfrequenz nach Photodynamischer Therapie und Bevacizumab im Vergleich zu Bevacizumab als Monotherapie bei altersabhängiger AMD nach einem Jahr Therapie : eine retrospektive klinische Analyse / Fabian Lehmann." Ulm : Universität Ulm. Medizinische Fakultät, 2012. http://d-nb.info/1024931250/34.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

Dimopoulou, Anastasia [Verfasser], and P. [Akademischer Betreuer] Szurman. "Intravitreale Bevacizumab-Therapie des zystoiden Makulaödems bei vaskulären retinalen Erkrankungen : Ergebnisse und prognostische Faktoren / Anastasia Dimopoulou ; Betreuer: P. Szurman." Tübingen : Universitätsbibliothek Tübingen, 2011. http://d-nb.info/1161464778/34.

Full text
APA, Harvard, Vancouver, ISO, and other styles
More sources

Books on the topic "Intravitreal bevacizumab"

1

Levy, David. Management of microvascular and associated complications. Oxford University Press, 2016. http://dx.doi.org/10.1093/med/9780198766452.003.0007.

Full text
Abstract:
While end-stage microvascular complications are now relatively uncommon, the burden of microvascular disease is still heavy. National diabetic retinopathy screening programmes have contributed to reducing advanced retinal disease, as has improved laser technology and vitreoretinal surgery. More recently intravitreal anti-VEGF agents (bevacizumab, ranibizumab, and aflibercept) have been effective in reducing visual loss from macular oedema. Diabetic nephropathy has a variable phenotype, and high rates of natural regression from microalbuminuria to normoalbuminuria mandate careful and regular re
APA, Harvard, Vancouver, ISO, and other styles

Book chapters on the topic "Intravitreal bevacizumab"

1

Penman, Alan D., Kimberly W. Crowder, and William M. Watkins. "Intravitreal Bevacizumab for Stage 3+ Retinopathy of Prematurity." In 50 Studies Every Ophthalmologist Should Know. Oxford University Press, 2020. http://dx.doi.org/10.1093/med/9780190050726.003.0028.

Full text
Abstract:
The Bevacizumab Eliminates the Angiogenic Threat of Retinopathy of Prematurity (BEAT-ROP) study was a randomized, controlled clinical trial to determine whether intravitreal bevacizumab monotherapy was an effective therapy for treating zone I or zone II posterior stage 3+ (stage 3 with plus disease) retinopathy of prematurity (ROP). Intravitreal bevacizumab, as compared with conventional laser therapy, showed a significant benefit for zone I but not zone II disease. Development of peripheral retinal vessels (with possible recurrence of ROP) continued after treatment with intravitreal bevacizum
APA, Harvard, Vancouver, ISO, and other styles
2

Manzano, Roberta PA, and Gholam A. Peyman. "Intravitreal toxicity of bevacizumab." In Vitreoretinal Surgical Techniques. Routledge, 2019. http://dx.doi.org/10.1201/9780203734315-67.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Penman, Alan D., Kimberly W. Crowder, and William M. Watkins. "Ranibizumab and Bevacizumab for Neovascular Age-Related Macular Degeneration." In 50 Studies Every Ophthalmologist Should Know. Oxford University Press, 2020. http://dx.doi.org/10.1093/med/9780190050726.003.0041.

Full text
Abstract:
The Comparison of Age-Related Macular Degeneration Treatments Trials (CATT) was a randomized, single-blind, noninferiority trial to evaluate the relative efficacy and safety of intravitreal injections of ranibizumab and bevacizumab (anti–vascular endothelial growth factor (VEGF) agents) for the treatment of neovascular age-related macular degeneration (AMD). At one year, bevacizumab and ranibizumab had equivalent effects on visual acuity when administered according to the same schedule: bevacizumab administered monthly was equivalent to ranibizumab administered monthly, with 8.0 and 8.5 letter
APA, Harvard, Vancouver, ISO, and other styles
4

King, Brian Christopher. "Efficacy of Intravitreal Bevacizumab for Stage 3+ Retinopathy of Prematurity." In 50 Studies Every Neonatologist Should Know, edited by Susanne Hay, Roger F. Soll, Barbara Schmidt, Haresh Kirpalani, and John Zupancic. Oxford University PressNew York, 2024. http://dx.doi.org/10.1093/med/9780197646953.003.0036.

Full text
Abstract:
Abstract The BEAT-ROP trial investigated whether bevacizumab, a vascular endothelial growth factor (VEGF) inhibitor, was an effective alternative to laser therapy for treatment of progressive disease. One hundred and fifty infants with stage 3+ zone I/zone II posterior disease were randomized to intravitreal bevacizumab or laser therapy. Disease recurrence was measured prior to 55 weeks’ postmenstrual age (PMA). Retinopathy recurred in fewer infants in the bevacizumab group versus the laser-therapy group (6% versus 26%; odds ratio 0.17, 95% confidence interval 0.05 to 0.53, p = 0.002). A signi
APA, Harvard, Vancouver, ISO, and other styles
5

Boscia, Francesco. "Chapter-43 Combined Cataract Extraction and Intravitreal Bevacizumab in Patients with Choroidal Neovascularization Due to Age-related Macular Degeneration." In Surgical Techniques in Ophthalmology (Retina and Vitreous Surgery). Jaypee Brothers Medical Publishers (P) Ltd., 2010. http://dx.doi.org/10.5005/jp/books/11712_43.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Vinković, Maja, Andrijana Kopić, and Tvrtka Benašić. "Anti-VEGF Treatment and Optical Coherence Tomography Biomarkers in Wet Age-Related Macular Degeneration." In Recent Advances and New Perspectives in Managing Macular Degeneration [Working Title]. IntechOpen, 2021. http://dx.doi.org/10.5772/intechopen.97689.

Full text
Abstract:
Age-related macular degeneration (AMD) is one of the most common causes of severe visual loss in middle and old-age population, and often leads to serious deterioration in quality of life. Currently, the first-line treatment for neovascular AMD (nAMD) are intravitreal injections of anti-vascular endothelial growth factor (VEGF) medications, including bevacizumab, ranibizumab, and aflibercept and also latest commercially available drug, brolucizumab. During initial examination and imaging and treatment follow-up for patients with nAMD, optical coherence tomography (OCT) is used to predict and a
APA, Harvard, Vancouver, ISO, and other styles
You might also be interested in the extended bibliographies on the topic 'Intravitreal bevacizumab' for particular source types:
Journal articles Dissertations / Theses
We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!

To the bibliography